Phase 2 N=7 HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
Multiple Sclerosis
Primary: Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients — 25.62; 22.58; 20.73 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=395 Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Asthma
Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 1.11; 0.46 Exacerbation per participant per year — p=< 0.001
Phase 3 N=192 N-Acetylcysteine for Youth Cannabis Use Disorder
Cannabis Use Disorder
Primary: Percentage of Urine Tests With Negative Cannabinoid Results During Treatment — 9.4; 14.0 Percentage
N/A N=8 Viewing Surface Electrical Stimulation on Pelvic Floor With Ultrasound
Pelvic Floor Disorders
Primary: Movement of the Bladder — 23.1 pixels
Phase 2 N=160 Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
High-grade Serous Ovarian Carcinoma · Ovarian Carcinoma
Primary: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) — 0.08; 0.04 Fold change
Phase 2 N=48 LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Product-related Unexpected Serious Adverse Events — 0; 0; 0 Participants
Phase 4 N=288 Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
Alcohol Use Disorder
Primary: Number of Participants With Continuous Sobriety According to Alcohol Timeline Follow Back — 66; 39 Participants
N/A N=216 Crowdsourcing to Reduce HIV Stigma Among Adolescents and Young Adults in Kazakhstan
Stigma, Social · HIV Testing
Primary: Mean Score Change in Total HIV Stigma Scale — 47.48; 47.89; 44.60; 47.32 units on a scale — p=0.083
N/A N=27 Micropulse for Suppression of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76
Phase 2 N=16 Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
Indolent Systemic Mastocytosis
Primary: Percent Change in Quality of Life (QoL) Using Mastocytosis Quality of Life Questionnaire (MC-QoL) — 38.98; 33.02 percentage of change in quality of life — p=0.7740
N/A N=15 Modulation of Sensory Acuity With Transcranial Magnetic Stimulation (TMS)
Speech
Primary: Somatosensory Acuity: Spatial Amplitude Discrimination Threshold (SDT) — 20.08; -8.07; 5.39; -2.81 change in threshold (µm)
Phase 1 N=38 Concentration-QT Study of Paroxetine in Healthy Adults
Anxiety Disorders
Primary: Change From Baseline in Corrected QT Interval by Fridericia (QTcF Interval) — 1.9; 1.0; 0.9; 2.2 Milliseconds
N/A N=285 Impact of BC Farmers' Market Nutrition Coupon Program on Diet Quality and Psychosocial Well-being of Low-income Adults
Diet, Healthy · Health Risk Behaviors
Primary: Difference Between Intervention and Control Groups in Mean Overall Diet Quality by Healthy Eating Index-2015 Scores Immediately Post-intervention (10-15 Weeks) — 63.6…
N/A N=19 Animal Assisted Interactions With Animal Robot in the Intensive Care Unit (ICU)
Acute Lymphoblastic Leukemia (ALL) · Critical Illness · Physical Therapy Modalities
Primary: Pain: Wrong-Baker FACES Pain Rating Scale — 3.94 units on a scale
Phase 3 N=445 A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
Allergy
Primary: Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS) — 7.10; 5.22 score on a scale — p=0.0036